| Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study. (NCT04587739) | University Hospital, Lille | 2021-01-31 |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma (NCT04728321) | Akeso | 2021-01-27 |
| The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (NCT04572633) | HistoSonics, Inc. | 2021-01-27 |
| Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib (NCT04327700) | Wake Forest University Health Sciences | 2021-01-26 |
| Optimization for Regorafenib in HCC (NCT04476329) | SC Liver Research Consortium, LLC | 2021-01-21 |
| Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres (NCT04903548) | Methodist Health System | 2021-01-08 |
| Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) (NCT04741165) | Taizhou Hanzhong biomedical co. LTD | 2021-01-07 |
| Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (NCT04803318) | Second Affiliated Hospital of Guangzhou Medical University | 2021-01-01 |
| TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT (NCT05535998) | Yunfei Yuan | 2021-01-01 |
| The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt (NCT05047146) | Sadat City University | 2021-01-01 |
| Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment (NCT04552236) | Assiut University | 2021-01-01 |
| Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC (NCT04920214) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-01-01 |
| Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation (NCT06248554) | Chen Xiaoping | 2021-01-01 |
| Pharmacogenetic of Doxorubicin in HCC. (NCT06313047) | Rehab Werida | 2021-01-01 |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma (NCT06333561) | Sun Yat-sen University | 2021-01-01 |
| Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC) (NCT05152498) | Beijing Ditan Hospital | 2021-01-01 |
| Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC (NCT05171309) | Nanfang Hospital, Southern Medical University | 2021-01-01 |
| The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study (NCT04909866) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-01-01 |
| HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama (NCT04627363) | Sun Yat-sen University | 2021-01-01 |
| PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC (NCT04974281) | Fudan University | 2021-01-01 |
| Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial (NCT04687163) | Sun Yat-sen University | 2020-12-30 |
| Perioperative Therapy for Hepatocellular Carcinoma (NCT04653389) | Zhejiang University | 2020-12-26 |
| Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study (NCT04680598) | Sun Yat-sen University | 2020-12-25 |
| A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma (NCT04635527) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-12-24 |
| Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC (NCT04639284) | Shanghai Zhongshan Hospital | 2020-12-23 |
| To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer (NCT04520906) | Suzhou Hengruihongyuan Medical Technology Co. LTD | 2020-12-17 |
| Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity (NCT04631731) | Western Sydney Local Health District | 2020-12-15 |
| Ablation Combined With PD-1 in HCC: Phase II Study (NCT04652440) | Sun Yat-sen University | 2020-12-15 |
| Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population (NCT06379334) | Peking Union Medical College Hospital | 2020-12-06 |
| Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma (NCT04642547) | RenJi Hospital | 2020-12-02 |
| Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma (NCT04523467) | Eastern Hepatobiliary Surgery Hospital | 2020-12-01 |
| Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor (NCT05502458) | Zhejiang Cancer Hospital | 2020-12-01 |
| Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) (NCT04541173) | Aiwu Ruth He, MD | 2020-11-30 |
| The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial (NCT04562428) | China Medical University Hospital | 2020-11-20 |
| Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers (NCT04682847) | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 2020-11-19 |
| Hepatocellular Carcinoma Surveillance in Cirrhotics (NCT04248816) | University of Pennsylvania | 2020-11-19 |
| Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers (NCT05431621) | Shanghai Zhongshan Hospital | 2020-11-15 |
| Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC (NCT04653701) | Juan José Ciampi Dopazo | 2020-11-14 |
| Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (NCT04823403) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-11-13 |
| SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (NCT04560894) | Sinocelltech Ltd. | 2020-11-11 |
| Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation (NCT04595864) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-11-01 |
| The Efficacy of Sequential RT After Triple Therapy for uHCC (NCT07052448) | Fujian Provincial Hospital | 2020-11-01 |
| Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs (NCT04770207) | Second Affiliated Hospital of Guangzhou Medical University | 2020-11-01 |
| Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma (NCT04652492) | Zhongda Hospital | 2020-10-27 |
| TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC (NCT04597970) | Peking University Cancer Hospital & Institute | 2020-10-20 |
| SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma (NCT04913480) | The University of Hong Kong | 2020-10-15 |
| Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE (NCT04569799) | Milton S. Hershey Medical Center | 2020-10-14 |
| Hepatobiliary Tumors Tissue Samples Acquisition (NCT04445532) | Peking Union Medical College Hospital | 2020-10-11 |
| TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial (NCT04531228) | Yunfei Yuan | 2020-10-11 |
| HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial (NCT04653818) | Alexandria University | 2020-10-05 |
| Yang Yin Fu Zheng Jie Du Therapy in HBV Associated Hepatocellular Carcinoma Based on the Platelet Count/Splenic Length-Diameter Ratio (NCT05154812) | Beijing Ditan Hospital | 2020-10-01 |
| Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy (NCT07186010) | Asan Medical Center | 2020-09-28 |
| NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors (NCT04550663) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-09-25 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol (NCT04178642) | University Hospital, Montpellier | 2020-09-22 |
| Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation (NCT04564313) | Third Affiliated Hospital, Sun Yat-Sen University | 2020-09-21 |
| Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC) (NCT03969576) | Air Force Military Medical University, China | 2020-09-15 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Dan Zandberg | 2020-09-14 |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC (NCT04518852) | Sichuan Cancer Hospital and Research Institute | 2020-09-14 |
| Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC (NCT04443309) | Peking Union Medical College Hospital | 2020-09-11 |
| TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma (NCT04559607) | Zhongda Hospital | 2020-09-11 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma (NCT04401800) | BeiGene | 2020-09-04 |
| Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma (NCT04340986) | Assistance Publique - Hôpitaux de Paris | 2020-09-02 |
| Surgical Therapy and Survival in HCC/ C.F. Zhang et al. (NCT04820712) | Linzhu Zhai | 2020-09-01 |
| Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation (NCT04555265) | Chinese University of Hong Kong | 2020-09-01 |
| FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy (NCT05662488) | Peking Union Medical College Hospital | 2020-09-01 |
| Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection (NCT03990974) | Sun Yat-sen University | 2020-09-01 |
| Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI) (NCT03172559) | University Health Network, Toronto | 2020-09-01 |
| Phenotyping Liver Cancer Registry (NCT04681274) | Assistance Publique - Hôpitaux de Paris | 2020-08-31 |
| Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer (NCT04523662) | Beijing Tsinghua Chang Gung Hospital | 2020-08-30 |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (NCT04459273) | Jonsson Comprehensive Cancer Center | 2020-08-27 |
| Effects of Anesthetic Methods on Hepatic Cancer Cell Function in Vitro (NCT04510935) | RenJi Hospital | 2020-08-20 |
| STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs (NCT04395118) | University of Texas Southwestern Medical Center | 2020-08-15 |
| Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial (NCT04518774) | Beijing 302 Hospital | 2020-08-15 |
| CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis (NCT04512833) | Beijing 302 Hospital | 2020-08-12 |
| Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma (NCT04472767) | University of California, Irvine | 2020-08-07 |
| Cabozantinib to Treat Recurrent Liver Cancer Post Transplant (NCT04204850) | University Health Network, Toronto | 2020-08-07 |
| HR Versus RFA for Early Stage HCC (NCT02169765) | Guangxi Medical University | 2020-08-01 |
| Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) (NCT04316182) | Fundacion Clinic per a la Recerca Biomédica | 2020-07-31 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function (NCT04454762) | Johannes Gutenberg University Mainz | 2020-07-22 |
| Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC (NCT04391348) | Assistance Publique - Hôpitaux de Paris | 2020-07-17 |
| Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma (NCT04368078) | Peking Union Medical College Hospital | 2020-07-11 |
| To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma. (NCT04443049) | Institute of Liver and Biliary Sciences, India | 2020-07-10 |
| Neo-TACE-HAIC for BCLC B Stage HCC (NCT04424043) | Sun Yat-sen University | 2020-07-08 |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma (NCT04444167) | Akeso | 2020-07-07 |
| Study of Automatic Image Fusion of a CT Volume With Ultrasound During Percutaneous Ablation Treatment of Hepatic Tumors (NCT04420026) | Assistance Publique - Hôpitaux de Paris | 2020-07-06 |
| Neoadjuvant Anti-PD1 in HCC (NCT05471674) | Dr Tan-to CHEUNG | 2020-07-03 |
| Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma (NCT05240404) | Xiangya Hospital of Central South University | 2020-07-01 |
| Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA) (NCT05088733) | Beijing Ditan Hospital | 2020-07-01 |
| Predictive Power of Share Wave Fibro Scan in HCC After HCV Infection (NCT05105828) | Assiut University | 2020-07-01 |
| Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients (NCT04483284) | Shanghai Zhongshan Hospital | 2020-06-24 |
| A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma (NCT04411706) | Xin-Hua Xu | 2020-06-21 |
| Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma (NCT04576572) | Inonu University | 2020-06-15 |
| Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC (NCT04124991) | Seoul National University Hospital | 2020-06-12 |
| Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma (NCT04847726) | Seoul National University Hospital | 2020-06-09 |
| Role of CEUS as a Secondary Diagnostic Modality (NCT04494022) | Seoul National University Hospital | 2020-06-08 |
| PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer (NCT04310540) | Mayo Clinic | 2020-06-05 |
| Irreversible Electroporation of Unresectable Liver Tumors (NCT04404647) | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | 2020-06-01 |
| SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma (NCT04434989) | Sun Yat-sen University | 2020-06-01 |